TICKERNERD
Menu
MMEDHealthcare · Medical Instruments & Supplies

MMED Stock Forecast: MiniMed Group, Inc. Price Predictions for 2026-2027

Last close, 5 Oct 2026
$20
+2.34% on the day

The 13 Wall Street analysts covering MiniMed Group, Inc. hold a median 12-month price target of $26 — +29.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 3 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$5.5B
Ticker Nerd rank
2 / 100
Median analyst target
$26
Analysts covering
13
Revenue$843.0M+16.4% y/y
Operating income$2.0M
Net income$0.0
Free cash flow−$90.0M
Quarterly, 6 quarters to 31 July 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.6%
1M
−13.4%
From high
−15.4%
From low
+86.7%
$11
$24
Range since 6 Mar 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

MMED stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MiniMed Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
2 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
49
Size
21
Momentum
20
Value
12
Issuance
10
Accruals
8
Growth
8
Volatility
4
Quality
2

Revisions (49): Analysts have, on balance, been raising their forecasts.

Quality (2): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MMED stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MMED, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 6 Mar 2026Adjusted close, US dollars
$10$15$20$25$30Apr 26Jul 26Oct 26MMEDHigh $29Median $26Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
11 Buy1 Hold1 Sell
Low $15Median $26High $29

The green dot is the last close — the median target sits +29.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
24 Sept 2026Truist SecuritiesInitiatesBuy$29
3 Sept 2026Morgan StanleyMaintainsOverweight$19 → $21
3 Sept 2026Morgan StanleyMaintainsOverweight—
2 Sept 2026B of A SecuritiesMaintainsBuy$24 → $28
2 Sept 2026B of A SecuritiesMaintainsBuy—
2 Sept 2026CitigroupMaintainsBuy$23 → $26
2 Sept 2026CitigroupMaintainsBuy—
2 Sept 2026Evercore ISI GroupMaintainsOutperform—
2 Sept 2026Evercore ISI GroupMaintainsOutperform$20 → $27
2 Sept 2026MizuhoMaintainsOutperform—
2 Sept 2026MizuhoMaintainsOutperform$21 → $26
2 Sept 2026UBSMaintainsBuy$25 → $28
2 Sept 2026UBSMaintainsBuy—
2 Sept 2026Wells FargoMaintainsOverweight—
2 Sept 2026Wells FargoMaintainsOverweight$22 → $26
1 Sept 2026BTIGMaintainsBuy$25 → $28
1 Sept 2026BTIGMaintainsBuy—
28 July 2026UBSAssumesBuy$25
4 June 2026Wells FargoMaintainsOverweight$26 → $22
4 June 2026Wells FargoMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MMED appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MMED vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

MMED vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Apr 26Jul 26Oct 26MMEDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MMED analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.4%
Analysts raising
4
Analysts cutting
2
Fundamentals

MiniMed Group, Inc. (MMED) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−15.2×

Cheaper than 95% of US stocks

Price / sales
1.7×

Cheaper than 55% of US stocks

Price / book
1.5×

Cheaper than 53% of US stocks

EV / EBITDA
18.9×

Cheaper than 17% of US stocks

Growth & margins
Revenue growth (YoY)
16.6%

Higher than 65% of US stocks

Earnings growth (YoY)
16.4%

Higher than 54% of US stocks

Gross margin
55.2%

Higher than 68% of US stocks

Operating margin
0.5%

Higher than 46% of US stocks

Net margin
−9.7%

Higher than 20% of US stocks

Returns & dividend
Return on equity
−8.7%

Higher than 37% of US stocks

Return on assets
−7.2%

Higher than 29% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

MiniMed Group, Inc. (MMED) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • MiniMed Group, Inc. has a market value of $5.5B and an enterprise value of $5.4B.

  • Revenue in the twelve months to 31 July 2026: $3.2B. The latest quarter grew 16.6% year on year.

  • Net income over the same four quarters: −$326.0M, a −10.1% net margin.

  • Free cash flow in the twelve months to 31 July 2026: −$316.0M.

  • Shares outstanding: 281.2M.

  • Trailing P/E: −15.2×; forward P/E: 30.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • MiniMed Group, Inc. employs 8,000 people — $403K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 July 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

MMED vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
MMEDMiniMed Group, Inc.$5.5B
2
STVNStevanato Group SpA$5.5B
68
TFXTeleflex, Inc.$5.5B
80
MMSIMerit Medical Systems, Inc.$5.1B
92
BLCOBausch + Lomb Corp.$6.1B
88
ICUIICU Medical, Inc.$3.9B
97
ATRAptarGroup, Inc.$7.9B
51

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MiniMed Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MMED news & analysis

Responding more frequently to MiniMed Smart MDI alerts linked to better glucose outcomes for people with diabetes

PRNewsWire · 5 Oct 2026positive

MediSafe... actually, MiniMed announced results from a six-month randomized trial showing that responding more frequently to Smart MDI alerts was linked to better glucose outcomes for people with diabetes. Higher responders achieved 8.1 percentage points more Time in Range and 0.6 percentage points lower HbA1c.

Why it matters — The trial results provide clinical evidence supporting the effectiveness of MiniMed's Smart MDI technology, which could strengthen the product's value proposition for people with diabetes.

Why Medtronic's $4 Billion MiniMed Exchange Offer Is Losing Its Allure

Barrons · 2 Oct 2026negative

Barron's reports that Medtronic's $4 billion tax-free exchange offer, in which Medtronic investors can swap their shares for MiniMed shares held by Medtronic in a split-off, is losing its appeal. The offer appears to be attracting less interest from investors.

Why it matters — Waning investor participation in the exchange offer could signal weakening demand for MiniMed shares and affect the supply and distribution of its stock.

DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care

Zacks Investment Research · 2 Oct 2026neutral

According to a Zacks Investment Research report, Dexcom sees room to expand continuous glucose monitor adoption, citing low awareness, reimbursement hurdles and rising GLP-1 use as factors creating new opportunities in Type 2 diabetes care.

Why it matters — A MMED watcher would care because the piece highlights growth dynamics in the Type 2 diabetes and continuous glucose monitoring space, a market context relevant to MiniMed's peer landscape.

MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary

PRNewsWire · 28 Sept 2026neutral

MiniMed announced that Sheila Denton has been appointed General Counsel and Corporate Secretary, as disclosed in a Sept. 28, 2026 press release.

Why it matters — A leadership appointment to the general counsel and corporate secretary roles is a governance-related development that MMED watchers may track for changes in the company's legal and administrative leadership.

Squeeze Watch: 10 Stocks With Over 33% Short Interest

Benzinga · 25 Sept 2026neutral

A Benzinga report identifies ten stocks with over 33% of their float sold short, each worth more than $2 billion, with the top company exceeding 80% short interest. The article covers this "squeeze watch" list broadly without singling out any specific issuer.

Why it matters — A MMED watcher would care because such high short interest can indicate market sentiment toward small-cap biotech and psychedelic stocks, though this item does not specifically mention MMED.

FAQ

Frequently asked questions about MMED stock

What is the MMED stock price forecast for 2026-2027?

The 13 Wall Street analysts covering MiniMed Group, Inc. have a median 12-month price target of $26, with estimates ranging from $15 to $29. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MMED stock a buy right now?

Of the 13 analysts covering MiniMed Group, Inc., 11 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks MiniMed Group, Inc. 2 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MMED?

As at 3 Oct 2026, MiniMed Group, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (49 of 100).

Will MMED stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +29.0% from the last close, and Ticker Nerd's factor model ranks MiniMed Group, Inc. 2 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MMED stock forecast for 2030?

No analyst covering MiniMed Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MMED are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $29 over the next 12 months.

What does MiniMed Group, Inc. do?

MiniMed Group, Inc. is a medical technology company focused on diabetes management.

What is the latest news on MMED?

The most recent item we track (PRNewsWire, 5 Oct 2026): "Responding more frequently to MiniMed Smart MDI alerts linked to better glucose outcomes for people with diabetes". MediSafe... actually, MiniMed announced results from a six-month randomized trial showing that responding more frequently to Smart MDI alerts was linked to better glucose outcomes for people with diabetes. Higher responders achieved 8.1 percentage points more Time in Range and 0.6 percentage points lower HbA1c.

Company

About MiniMed Group, Inc.

MiniMed Group, Inc. is a medical technology company focused on diabetes management. MiniMed develops, manufactures, and markets a connected ecosystem of products and services that includes insulin pumps, continuous glucose monitors, smart insulin pens, consumables, and supporting software. Its offerings are designed for people with type 1 diabetes and insulin-requiring type 2 diabetes, serving individual users, healthcare providers, distributors, and other institutions. The company’s portfolio centers on automated insulin delivery systems and smart multiple daily injection solutions, combining hardware, sensing technology, dosing algorithms, and digital health tools. Headquartered in Northridge, California, MiniMed Group plays a significant role in the diabetes care market by providing integrated technologies that support insulin therapy and glucose management.

CEO Ms. Que Thanh Dallara · 8,000 employees · United States · https://www.minimed.com